齐默巴奥米特 ZBH 深 沪
等待开盘 05-12 09:30:00 美东时间
79.58
-2.730
-3.32%
华盛通- 最 高84.495
- 今 开82.06
- 成交量 196.20万股
- 最 低 79.12
- 昨 收 82.31
- 总市值 1671.18万
- 52周最高 108.29
- 市盈率 静 41.69
- 换手率 934.30%
- 52周最低 79.12
- 委 比 -25.79%
- 总股本 0.00亿
- 历史最高 175.36
- 量 比 0.60
- 振 幅 6.53%
- 历史最低 33.68
- 每 手 1
- 风险率 5.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BTIG Downgrades Zimmer Biomet Holdings to Neutral
BTIG analyst Ryan Zimmerman downgrades Zimmer Biomet Holdings (NYSE:ZBH) from Buy to Neutral.
03-23 17:40
Zimmer Biomet Holdings Q4 Earnings Assessment
Zimmer Biomet Holdings (NYSE:ZBH) just disclosed its Q4 earnings on Tuesday, Fe...
02-10 19:32
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology
Treace Medical Concepts filed a patent infringement lawsuit against Zimmer Biomet and Paragon 28, alleging violation of four patents related to its Lapiplasty® technology. The company, a leader in bunion correction systems, seeks injunctive relief and damages to protect its innovative research and technology. Treace holds 80 U.S. patents, 26 international patents, and has over 150 pending applications.
2025-06-05 17:00
关税乌云压顶！巴克莱点名美股医疗器械行业“抗压王”与“重灾区”
巴克莱银行在一份研究报告中分析了特朗普政府新关税政策对医疗器械行业的影响，报告指出，雅培(ABT.US)和百特国际(BAX.US)将是受影响最小的公司之列，而强生(JNJ.US)和美敦力(MDT.US)则会是受影响最大的公司。 巴克莱分析师表示，在大型医疗科技公司中，雅培、百特国际、爱德华生命科学(EW.US)和直觉外科公司(ISRG.US)等公司(“增持”评级)，以及齐默巴奥米特控股(ZBH.US)(“减持”评级)都是受关税影响最小的公司。 同样，根据这家研究经纪公司的分析师的观点，在中小盘股领域，Globus Medical(GMED.US)、阿尔法泰克(ATEC.US)和Tandem D...
2025-04-17 11:49
Needham Reiterates Hold on Zimmer Biomet Holdings
Needham analyst Mike Matson reiterates Zimmer Biomet Holdings (NYSE:ZBH) with a Hold.
2024-09-17 17:42
Oracle To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a comple...
2024-09-13 23:54
Watching Zimmer Biomet; Traders Circulate CEO Comments Made At The Wells Fargo 2024 Healthcare Conference Saying "Its Newly Implemented Enterprise Resource Planning Failed To Perform As Expected, And The Issue Is Likely To Impact Its H2 Revenue, The Issue Will Likely Impact Around 1% Of Its Revenue This Year And That By The Time We Exit Q4, It Should Be Largely Resolved"
Shares of Zimmer Biomet (NYSE:ZBH) fell sharply on Thursday after the orthopedic device maker said its newly implemented enterprise resource planning (ERP) failed to perform as expected, and the issue is likely to impact
2024-09-05 23:46
Canaccord Genuity Adjusts Price Target on Zimmer Biomet to $120 From $130, Maintains Hold Rating
07:37 AM EDT, 08/20/2024 (MT Newswires) -- Zimmer Biomet Holdings (ZBH) has an average rating of hold and price targets ranging from $107 to $175, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North Ame...
2024-08-20 19:37
